[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Evidence-Based Dermatology: Research Commentary
September 2000

Rational Follow-up Recommendations for Patients With Melanoma

Author Affiliations

DamianoAbeniMD, MPHMichaelBigbyMDPaoloPasquiniMD, MPHMoysesSzkloMD, MPH, DrPHHywelWilliamsMSc, PhD, FRCP

Arch Dermatol. 2000;136(9):1145-1148. doi:10.1001/archderm.136.9.1145

Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanomaPoo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, Brown J, Fischer D, Bolognia J, Buzaid ACCancer. 1999;86:2252-2258.

More than 44,000 new cases of melanoma are detected annually in the United States, and the number is steadily increasing. The majority of patients are treated with surgical excision and may, in addition, undergo sentinel node mapping, lymph node dissection, and adjunctive treatment. The purpose of this study was to develop rational, evidence-based guidelines for following up patients with 1983 American Joint Committee on Cancer stage I (<1.5 mm thick), II (localized disease >1.5 mm thick), and III (local nodal or in-transit metastases) melanoma.

First Page Preview View Large
First page PDF preview
First page PDF preview